Curaleaf Holdings (CURLF) Return on Capital Employed (2020 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Return on Capital Employed of 0.46% for Q4 2024, down 63.0% year-on-year from 1.24% in Q1 2024, and down 26.21% on a QoQ basis from 0.62% in Q3 2024.
Curaleaf Holdings (CURLF) Return on Capital Employed (2020 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Return on Capital Employed for 5 consecutive years, with 0.46% the latest figure, recorded in Q4 2024.
- Quarterly Return on Capital Employed fell 63.0% year-over-year to 0.46% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.46% (down 63.0% YoY) and the FY2025 annual result came in at 0.98%, up 4.0% from the prior year.
- Return on Capital Employed fell to 0.46% in Q4 2024 per CURLF's latest filing, from 0.62% in the prior quarter.
- Over the last five years, Return on Capital Employed for CURLF reached as high as 40.6% in Q3 2022 and fell as low as 2.35% in Q2 2023.
- A 5-year average of 5.28% and a median of 2.49% in 2020 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 3515 bps — and 2023, when it plunged 4254 bps.
- Year by year, Return on Capital Employed stood at 3.08% in 2020, then surged by 180 bps to 8.63% in 2021, then plunged by 78 bps to 1.89% in 2022, then slumped by 43 bps to 1.08% in 2023, then sank by 58 bps to 0.46% in 2024.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 0.46%, 0.62%, and 1.08% for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.46% |
| Sep 30, 2024 | 0.62% |
| Dec 31, 2023 | 1.08% |
| Sep 30, 2023 | -1.94% |
| Jun 30, 2023 | -2.35% |
| Dec 31, 2022 | 1.89% |
| Sep 30, 2022 | 40.60% |
| Jun 30, 2022 | 7.44% |
| Mar 31, 2022 | -0.03% |
| Dec 31, 2021 | 8.63% |
| Sep 30, 2021 | 5.45% |
| Jun 30, 2021 | 4.77% |
| Mar 31, 2021 | 4.25% |
| Dec 31, 2020 | 3.08% |